Project Grant R01CA299084
Award Date 6/9/26
Completion Date 5/31/31
Dollars Obligated $693K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
- Federal Grant Award Summary Duke University's Office of Research Administration received a $411,152 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded September 5, 2025, with completion targeted for August 31, 2027. This research initiative focuses on identifying and validating noncovalent protein interactions of mutant KRAS (MKRAS) inhibitors, addressing a critical gap in understanding off-target effects of recently FDA-approved...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a five-year Project Grant totaling $675,009 to the University of California, San Francisco (UCSF) beginning August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395). This grant supports the development of covalent inhibitors targeting RAS Q61 mutations, which occur in approximately 90% of RAS Q61-mutant cancers including hematologic malignancies, melanoma, thyroid cancer, and pediatric cancers. The research,...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $120,403 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded on June 1, 2026, with a completion date of May 31, 2027. This award supports research development focused on pancreatic ductal adenocarcinoma (PDAC) detection and patient risk stratification. The project delivers ultrasensitive maximum depth sequencing (MDS) services...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $375,150 to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) to fund a five-year research initiative (September 1, 2025 – August 31, 2030). The research addresses innate resistance mechanisms to KRAS inhibitors in cancer treatment, focusing on the role of the RhoA-ROCK-Myosin IIA cytoskeletal axis in promoting drug-tolerant persister...
- Federal Grant Award Summary New York University School of Medicine received a $435,827 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective June 4, 2025, with completion targeted for May 31, 2027. The grant supports research entitled "Exploiting Synthetic Lethality to Enhance KRAS Inhibitor Therapy of Cancer," which investigates combination therapeutic strategies to overcome intrinsic and emergent resistance to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill $769,260 under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research identifying immune-mediated mechanisms of RAS inhibitor efficacy and resistance in pancreatic ductal adenocarcinoma (PDAC). The project, which commenced on April 10, 2026, and concludes on March 31, 2028, focuses on delineating how remodeling of tumor-immune interactions contributes...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University's Health Sciences Division a $682,673 Project Grant under the Cancer Treatment Research program (CFDA 93.395) for research on "Adaptation and Evolution of Resistance to Pan-RAS Inhibition in Pancreatic Ductal Adenocarcinoma." The five-year project, spanning May 1, 2026 through April 30, 2031, supports fundamental and applied research investigating mechanisms of tumor resistance to pan-RAS...
- Federal Grant Award Summary Duke University's Office of Research Administration was awarded $402,135 by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, with completion targeted for April 30, 2029. The project involves the development and optimization of SCHICAR (Single-Cell High-resolution 3D Genome Interactions, Chromatin Accessibility, and transcRiptomes), a novel tri-modal single-cell platform designed to simultaneously capture...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $415,257 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on April 24, 2026, with completion targeted for March 31, 2028. The research project addresses colorectal cancer (CRC) recurrence by developing and implementing novel microfluidics-based technology to isolate, culture, and characterize minimal residual disease (MRD)—cancer cells...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $395,846 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct fundamental research on therapeutic targeting of SMARCAL1 in therapy-resistant gliomas. The award, effective April 1, 2026 through March 31, 2031, supports investigation of SMARCAL1 as a synthetic lethal vulnerability in Alternative Lengthening of Telomeres (ALT)-positive...